F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comGufic BioSciences Ltd is one of India’s fastest-growing pharmaceutical companies, recognized for its innovation in injectables, active pharmaceutical ingredients (APIs), and herbal formulations. With a legacy of quality and research-driven growth, Gufic BioSciences has established itself as a trusted name in the Indian pharma industry.
In this article, we’ll analyze Gufic BioSciences Ltd’s share price target from 2025 to 2030, its current performance, shareholding pattern, and future investment potential.
| Detail | Value |
|---|---|
| Open | ₹334.30 |
| Previous Close | ₹332.65 |
| Day’s High | ₹334.55 |
| Day’s Low | ₹321.65 |
| VWAP | ₹325.41 |
| Volume | 132,875 |
| Value (Lacs) | ₹430.38 |
| Market Capitalization (Cr.) | ₹3,248 |
| Beta (Volatility) | 0.92 |
| Upper Circuit Limit | ₹399.15 |
| Lower Circuit Limit | ₹266.15 |
| 52-Week High | ₹504.25 |
| 52-Week Low | ₹298.80 |
| Face Value | ₹1 |
| All-Time High | ₹504.25 |
| All-Time Low | ₹2.55 |
Founded several decades ago, Gufic BioSciences Ltd has evolved from a small pharmaceutical player into a major manufacturer of lyophilized injections, antibiotics, herbal medicines, and APIs. The company focuses heavily on innovation, exports, and therapeutic diversification.
Gufic’s strong R&D foundation and modern manufacturing facilities have made it a reliable partner for healthcare professionals in India and abroad.
Leading producer of lyophilized injectables in India
Diversified portfolio including anti-infectives, fertility, and herbal products
Expanding global presence with exports to over 20 countries
R&D-driven growth strategy with focus on oncology and critical care
Strong domestic distribution network and partnerships
| Investor Type | Holding (%) |
|---|---|
| Promoters | 72.50% |
| Retail and Others | 23.51% |
| Mutual Funds | 3.48% |
| Foreign Institutions | 0.34% |
| Other Domestic Institutions | 0.18% |
The high promoter holding of 72.50% indicates strong promoter confidence, while steady retail participation reflects long-term investor trust.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 340 | 370 |
| 2026 | 385 | 420 |
| 2027 | 430 | 470 |
| 2028 | 480 | 520 |
| 2029 | 525 | 570 |
| 2030 | 575 | 630 |
These targets are based on the company’s financial performance, R&D growth, capacity expansion, and sector outlook in the pharmaceutical industry.
By 2025, Gufic is expected to maintain steady performance, driven by consistent sales in domestic and export markets.
Why?
Strong product demand in injectables and herbal categories
Expansion in hospital-based sales channels
Moderate beta (0.92) indicating stability against market volatility
Investment Advice: A good entry point for long-term investors; consider staggered buying for better average cost.
In 2026, the company could see margin improvement with newer high-value products entering the market.
Why?
Increased R&D investment in novel drug delivery systems
Focus on oncology and fertility treatments
Steady export performance across regulated markets
Investment Advice: Hold for mid-term growth; watch quarterly earnings and R&D announcements.
Gufic’s growing export revenue may boost profitability in 2027.
Why?
New international partnerships and supply contracts
Better cost efficiency through automation and scale
Continued focus on high-margin products
Investment Advice: Suitable for investors seeking compounding returns over 3+ years.
By 2028, Gufic could emerge as one of the top mid-sized pharma exporters from India.
Why?
Enhanced API production capacity
Diversification across therapy areas
Improved cash flows and reduced debt levels
Investment Advice: Long-term investors can continue holding; dividend payouts may also increase.
A period of strong performance is expected as the pharma sector benefits from global healthcare demand.
Why?
Increasing global pharmaceutical outsourcing to India
Strong domestic hospital network
Healthy profit margins backed by innovation
Investment Advice: Continue holding; the stock may deliver attractive CAGR returns.
By 2030, Gufic BioSciences could establish itself as a major global healthcare player.
Why?
Innovation-led growth and sustainable business model
Potential expansion into biosimilars and complex generics
Consistent revenue and profit growth over the decade
Investment Advice: Excellent option for long-term investors focused on healthcare and pharma growth themes.
Yes. Gufic BioSciences Ltd presents a strong long-term investment opportunity in the healthcare and pharmaceutical sector. Its emphasis on R&D, product innovation, and export expansion makes it a potential multibagger over time.
High promoter holding (72.50%) ensures stability and commitment
Strong R&D pipeline and innovation focus
Growing international business presence
Consistent profitability and market capitalization above ₹3,000 crore
Regulatory risks in export markets
Rising competition in generic injectables
Dependency on a few high-revenue therapeutic segments
Always consult a certified financial advisor before investing.
Gufic BioSciences Ltd continues to strengthen its position in India’s pharmaceutical industry through innovation and expansion. With a market cap of ₹3,248 crore and a 52-week range between ₹298.80 and ₹504.25, the company reflects both resilience and potential for strong growth.
Analysts predict that Gufic BioSciences’ share price could reach ₹630 by 2030, supported by a robust pipeline, global expansion, and healthy financial performance.
For investors seeking exposure to India’s thriving pharma sector, Gufic BioSciences Ltd is a promising stock for long-term wealth creation.
1. What is the current share price of Gufic BioSciences Ltd?
As of October 2025, the share trades around ₹334.
2. What is the share price target for Gufic BioSciences in 2025?
The 2025 target is projected between ₹340 and ₹370.
3. Is Gufic BioSciences a good long-term investment?
Yes, the company’s R&D focus and export expansion make it attractive for long-term investors.
4. What is Gufic BioSciences’ 52-week high and low?
The 52-week high is ₹504.25 and the low is ₹298.80.
5. What is the promoter holding in Gufic BioSciences Ltd?
Promoters hold 72.50% of the company’s total shares.
6. What is the expected Gufic BioSciences share price in 2030?
Analysts expect the share to trade between ₹575 and ₹630 by 2030.
Disclaimer: This article is for educational and informational purposes only. Investors are advised to perform their own research or consult a financial expert before making investment decisions.
Register & Login